However, after 9.6 months of oral ocitinib treatment, patients with advanced lung adenocarcinoma and EGFR T790M-positive mutations invariably exhibit acquired resistance to ocitinib, which results in disease progression and impacts the clinical prognosis of patients (165). The gene discussed is EGFR; the disease is lung adenocarcinoma.